News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,053 Results
Type
Article (63288)
Company Profile (305)
Press Release (639460)
Section
Business (195521)
Career Advice (2843)
Deals (36168)
Drug Delivery (108)
Drug Development (83344)
Employer Resources (166)
FDA (16756)
Job Trends (15215)
News (341504)
Policy (34033)
Tag
Academia (2813)
Alliances (49035)
Alzheimer's disease (1238)
Approvals (16654)
Artificial intelligence (126)
Bankruptcy (327)
Best Places to Work (11718)
Biosimilars (77)
Biotechnology (227)
Breast cancer (103)
Cancer (901)
Career advice (2394)
Cell therapy (217)
Clinical research (65549)
Collaboration (312)
Compensation (141)
COVID-19 (2680)
Cystic fibrosis (83)
Data (777)
Diabetes (130)
Diagnostics (6384)
Drug pricing (89)
Earnings (70864)
Employer resources (147)
Events (106723)
Executive appointments (238)
FDA (17161)
Funding (273)
Gene therapy (163)
GLP-1 (607)
Government (4754)
Healthcare (19674)
Infectious disease (2749)
Inflammatory bowel disease (107)
Interviews (533)
IPO (16552)
Job creations (3797)
Job search strategy (2020)
Layoffs (466)
Legal (8158)
Lung cancer (162)
Manufacturing (158)
Medical device (13470)
Medtech (13475)
Mergers & acquisitions (19619)
Metabolic disorders (372)
Neuroscience (1481)
NextGen Class of 2024 (6912)
Non-profit (4742)
Northern California (1102)
Obesity (221)
Opinion (232)
Patents (97)
People (59845)
Phase I (20362)
Phase II (28733)
Phase III (21546)
Pipeline (193)
Postmarket research (2762)
Preclinical (8770)
Radiopharmaceuticals (256)
Rare diseases (194)
Real estate (6327)
Regulatory (22384)
Research institute (2516)
Resumes & cover letters (437)
Southern California (1014)
Startups (3631)
United States (11009)
Vaccines (585)
Weight loss (180)
Date
Last 7 days (686)
Last 30 days (2727)
Last 365 days (36904)
2024 (30102)
2023 (40792)
2022 (51970)
2021 (56812)
2020 (55460)
2019 (48581)
2018 (37010)
2017 (33920)
2016 (33363)
2015 (38972)
2014 (31910)
2013 (31028)
2012 (29413)
2011 (29695)
2010 (28032)
Location
Africa (955)
Arizona (152)
Asia (41749)
Australia (7326)
California (2507)
Canada (1099)
China (198)
Colorado (110)
Connecticut (113)
Europe (96119)
Florida (362)
Georgia (94)
Illinois (320)
Indiana (169)
Kansas (95)
Maryland (487)
Massachusetts (2091)
Michigan (145)
Minnesota (251)
New Jersey (771)
New York (765)
North Carolina (719)
Northern California (1102)
Ohio (123)
Pennsylvania (692)
South America (1305)
Southern California (1014)
Texas (351)
Washington State (299)
703,053 Results for "paragon gene therapy a unit of catalent biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
May 8, 2024
·
2 min read
Deals
Amid Novo Buy, Catalent Offloads New Jersey Facility to Ardena
European CDMO Ardena will buy Catalent’s oral solids manufacturing facility in Somerset, N.J.
October 14, 2024
·
1 min read
·
Annalee Armstrong
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
Podcast
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo’s purchase of Catalent; and other news.
October 16, 2024
·
1 min read
·
Heather McKenzie
Editorial
Eyes, Ears Get Their Due With Cell and Gene Therapy
With promising early results, cell and gene therapies are making headway against both rare and common ocular and auditory diseases.
September 3, 2024
·
4 min read
·
Heather McKenzie
Cell and gene therapy
Big Pharma’s Interest Grows in Evolving Cell and Gene Therapy Sector
Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.
October 9, 2024
·
4 min read
·
Greg Slabodkin
Regulatory
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy candidate, eliminating the need for an additional registrational study and potentially shortening the time-to-market by three years.
October 23, 2024
·
2 min read
·
Tristan Manalac
Gene therapy
Roche Inks Potential $1B Gene Therapy Deal With Dyno, Eyes Neurological Diseases
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’
in vivo
gene therapy delivery technology, which synthesizes virus capsids with better functionality and manufacturability.
October 24, 2024
·
2 min read
·
Tristan Manalac
Layoffs
Astellas Gene Therapies to Close Biomanufacturing Facility, Affecting About 100 Employees
Astellas Gene Therapies is closing its San Francisco biomanufacturing facility, shifting gene therapy manufacturing to North Carolina, cutting at least 17 employees and affecting dozens more.
September 3, 2024
·
1 min read
·
Angela Gabriel
Gene therapy
4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies
4D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for annualized standard-of-care injections in patients with wet age-related macular degeneration.
September 19, 2024
·
2 min read
·
Tristan Manalac
1 of 70,306
Next
